2 Matching Annotations
  1. May 2019
    1. Articles in the Lancet, Lancet Oncology, JAMA, JAMA Oncology, and Journal of Clinical Oncology published between January 2016 and June 2018 were searched.

      Why was NEJM excluded?

    1. first target the patients at highest risk of relapse;

      Clinical trials will most certainly first include those patients with the highest risk of relapse. However, long term, everything will depend on the risk/ benefit trade off: if an effective, simple, well-tolerated and cost-effective treatment was available (let's imagine a single short low-dose PD1 for any early Melanoma patient) that prevented progression for most patients would be very different from a highly toxic, expensive treatment that doesn't work for everyone (think Ipi 10mg/kg adjuvant)- so everything is in the trade-off